BOSTON, Nov. 13 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "Injecting Confidence to the Viprinex(TM) Mission by a Successful $60m Offering; Mountains Do Move".
This review is available at our website: http://www.scimitarequity.com.
Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com.
Scimitar Equity Research, Inc. provides sponsored equity research of
emerging healthcare companies for the investing communities. We certify
that all the views expressed in this review, accurately reflect our
personal views about NTII (NASDAQ) and its or their securities. No part of
our compensation was, is, or will be, directly or indirectly, related to
the specific recommendations or views contained in this review and we will
not have any investment banking relationships or personal investment in any
sponsored company. Investors are advised that this analysis and review is
issued solely for informational purposes and is not to be construed as an
offer to sell or the solicitation of an offer to buy. Scimitar was paid for
preparing this review. This analysis and review does not have regard to the
specific investment objectives, financial situation and the information
contained herein is
|SOURCE Scimitar Equity Research, Inc.|
Copyright©2007 PR Newswire.
All rights reserved